Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent WHO Grade 4 Glioma Clear all
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
Biological
Lead sponsor
T-MAXIMUM Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 21, 2026, 6:27 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Malignant Glioma
Interventions
D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced May 21, 2026, 6:27 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
Interventions
Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
415
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 289 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
Interventions
Vorinostat, Bevacizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 120 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide, Triapine
Procedure · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma
Interventions
Depatuxizumab mafodotin, Temozolomide, Lomustine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Up to 99 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pheresis, Surgical Procedure
Biological · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
Interventions
CMV-DCs with GM-CSF, Td (tetanus toxoid)
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
0 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab
Biological · Procedure · Other + 1 more
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Glioma
Interventions
lerapolturev, Lomustine
Biological · Drug
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced May 21, 2026, 6:27 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
Drug
Lead sponsor
Epitopoietic Research Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
High-grade Glioma, WHO Grade Ⅳ Glioma
Interventions
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
Biological
Lead sponsor
Tcelltech Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
XL765 (SAR245409), XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced May 21, 2026, 6:27 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma
Interventions
Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Glioma
Interventions
Retreatment Rhenium Liposome
Drug
Lead sponsor
Plus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Progressive Disease
Interventions
FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
Biological · Procedure · Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Interventions
Debio 0123, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Chicago, Illinois • New York, New York • Dallas, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 6:27 PM EDT
Active, not recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, Glioma, Glioblastoma Multiforme, Glioma, Malignant
Interventions
AZD1390
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced May 21, 2026, 6:27 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, Mismatch Repair Deficiency
Interventions
Pembrolizumab, Navifus Focused Ultrasound Sonification
Drug · Device
Lead sponsor
Jennifer Leddon
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced May 21, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
GBM, Glioblastoma, Glioma, Malignant Glioma
Interventions
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced May 21, 2026, 6:27 PM EDT